{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:06:49Z","timestamp":1784304409302,"version":"3.55.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Hormonal contraceptive use has important implications for both reproductive and general health. However, the patterns and trends of short-acting hormonal contraceptive use among US premenopausal females remain insufficiently characterized.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate trends in and factors associated with prescribed short-acting hormonal contraceptive use among US premenopausal females.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Serial, cross-sectional analyses were conducted using US nationally representative data from the National Health and Nutrition Examination Survey (NHANES), including 10 survey cycles between 1999 to 2000 and 2017 to 2020 (before the COVID-19 pandemic). Participants included noninstitutionalized premenopausal females aged 15 years to younger than 60 years without a history of breast cancer. Data were analyzed from January to November 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n NHANES cycle.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The prevalence of prescribed short-acting hormonal contraceptive use was extracted from the prescription medication data collected during household interviews. Data primarily reflect oral contraceptives and were categorized as combined estrogen and progestin or progestin-only formulations.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Data on 15\u202f531 premenopausal females (14.7% aged 15 to &amp;lt;20 years, 59.3% aged 20 to &amp;lt;40 years, 26.1% aged 40 to &amp;lt;60 years) were analyzed. Participants predominantly had an educational level higher than high school (59.8%), were privately insured (59.3%), and never smoked (58.7%). From 1999 to 2020, the prevalence of prescribed short-acting hormonal contraceptive use significantly increased from 5.2% (95% CI, 2.2%-11.5%) to 15.1% (95% CI, 10.7%-20.7%) for females aged 15 to younger than 20 years, was stable for females aged 20 to younger than 40 years (16.7% [95% CI, 13.2%-21.0%] to 13.3% [95% CI, 10.7%-16.4%]), and remained low among those aged 40 to younger than 60 years (3.8% [95% CI, 1.5%-9.3%] to 7.0% [95% CI, 4.0%-12.1%]). Compared with non-Hispanic White females, non-Hispanic Black and Hispanic females had lower prevalence of use and exhibited the greatest relative increases (prevalence ratio, 3.7 [95% CI, 1.0-13.7] among non-Hispanic Black females and 1.8 [95% CI, 0.9-3.7] among Hispanic females) from 1999 to 2020. Progestin-only formulations accounted for 0.4% (95% CI, 0.1%-2.5%) of the prescribed short-acting hormonal contraceptive prescriptions in 1999 to 2000 and remained low (5.2% [95% CI, 3.0%-8.9%)] in 2017-2020. The prevalence of short-acting hormonal contraceptive use varied by race and ethnicity in all age groups, by family income to poverty ratio, educational attainment, health insurance coverage, marital status, and weight status among females aged 20 to younger than 40 years and by family income to poverty ratio and smoking status among females aged 40 to younger than 60 years.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this serial cross-sectional study of US premenopausal females, prescribed short-acting hormonal contraceptive use increased among females aged 15 to younger than 20 years and among non-Hispanic Black and Hispanic females. Across all groups, the use of progestin-only formulations remained low over time.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.23880","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:30:23Z","timestamp":1784302223000},"page":"e2623880","source":"Crossref","is-referenced-by-count":0,"title":["Prescribed Short-Acting Hormonal Contraceptive Use Among Premenopausal Females"],"prefix":"10.1001","volume":"9","author":[{"given":"Israel","family":"Bacha","sequence":"first","affiliation":[{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleepon","family":"Uttamapinan","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Harsanyi","sequence":"additional","affiliation":[{"name":"Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Liberty","sequence":"additional","affiliation":[{"name":"Department of Obstetrics & Gynecology, Division of Complex Family Planning, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cancer Epidemiology and Prevention Research, Cancer Care Alberta, Calgary, Alberta, Canada"},{"name":"Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetunji T.","family":"Toriola","sequence":"additional","affiliation":[{"name":"Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri"},{"name":"Alvin J. Siteman Cancer Centre, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"2","key":"zoi260671r1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jhmas\/57.2.117","article-title":"Women\u2019s trials: the approval of the first oral contraceptive pill in the United States and Great Britain.","volume":"57","author":"Junod","year":"2002","journal-title":"J Hist Med Allied Sci"},{"key":"zoi260671r2","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.3109\/13625187.2010.513071","article-title":"History of oral contraception.","volume":"15","author":"Dhont","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"zoi260671r3","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.ajog.2011.06.057","article-title":"The state of hormonal contraception today: benefits and risks of hormonal contraceptives: combined estrogen and progestin contraceptives.","volume":"205","author":"Shulman","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"zoi260671r4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/17425255.2023.2279752","article-title":"Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications.","volume":"19","author":"Battipaglia","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"zoi260671r5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/jnci\/djae282","article-title":"Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.","volume":"117","author":"Tuesley","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"zoi260671r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.02.002","author":"Iversen","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"zoi260671r7","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1158\/0008-5472.CAN-20-2476","article-title":"Time-dependent effects of oral contraceptive use on breast, ovarian, and endometrial cancers.","volume":"81","author":"Karlsson","year":"2021","journal-title":"Cancer Res"},{"issue":"388","key":"zoi260671r8","first-page":"1","article-title":"Current contraceptive status among women aged 15-49: United States, 2017-2019.","author":"Daniels","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"62","key":"zoi260671r9","first-page":"1","article-title":"Contraceptive methods women have ever used: United States, 1982-2010.","author":"Daniels","year":"2013","journal-title":"Natl Health Stat Report"},{"issue":"539","key":"zoi260671r10","article-title":"Current contraceptive status among females ages 15-49: United States, 2022-2023.","author":"Daniels","year":"2025","journal-title":"NCHS Data Brief"},{"issue":"190","key":"zoi260671r12","first-page":"1","article-title":"National Health and Nutrition Examination Survey, 2017-March 2020 prepandemic file: sample design, estimation, and analytic guidelines.","author":"Akinbami","year":"2022","journal-title":"Vital Health Stat 1"},{"issue":"155","key":"zoi260671r14","first-page":"1","article-title":"The National Health and Nutrition Examination Survey: sample design, 1999-2006.","author":"Curtin","year":"2012","journal-title":"Vital Health Stat 2"},{"issue":"6","key":"zoi260671r15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s10552-021-01410-8","article-title":"Trends in oral contraceptive and intrauterine device use among reproductive-aged women in the US from 1999 to 2017.","volume":"32","author":"King","year":"2021","journal-title":"Cancer Causes Control"},{"issue":"14","key":"zoi260671r16","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJMoa1400506","article-title":"Provision of no-cost, long-acting contraception and teenage pregnancy.","volume":"371","author":"Secura","year":"2014","journal-title":"N Engl J Med"},{"issue":"195","key":"zoi260671r17","first-page":"1","article-title":"Contraceptive methods women have ever used: United States, 2015-2019.","author":"Daniels","year":"2023","journal-title":"Natl Health Stat Report"},{"issue":"4","key":"zoi260671r18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.contraception.2017.07.007","article-title":"Under (implicit) pressure: young Black and Latina women\u2019s perceptions of contraceptive care.","volume":"96","author":"Gomez","year":"2017","journal-title":"Contraception"},{"issue":"11","key":"zoi260671r19","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1177\/15409996251360908","article-title":"Clinician implicit racial bias and contraceptive counseling in the United States.","volume":"34","author":"Morrell","year":"2025","journal-title":"J Womens Health (Larchmt)"},{"issue":"3","key":"zoi260671r20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1363\/4318111","article-title":"Race, ethnicity and differences in contraception among low-income women: methods received by Family PACT clients, California, 2001-2007.","volume":"43","author":"Dehlendorf","year":"2011","journal-title":"Perspect Sex Reprod Health"},{"key":"zoi260671r21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.contraception.2022.08.002","article-title":"Association of Title X clinic status with receipt of person-centered contraceptive counseling: a population-based study.","volume":"115","author":"Hansen","year":"2022","journal-title":"Contraception"},{"issue":"3","key":"zoi260671r22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1363\/psrh.12245","article-title":"The status of person-centered contraceptive care in the United States: results from a nationally representative sample.","volume":"55","author":"Wingo","year":"2023","journal-title":"Perspect Sex Reprod Health"},{"issue":"4","key":"zoi260671r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7304a1","article-title":"U.S. medical eligibility criteria for contraceptive use, 2024.","volume":"73","author":"Nguyen","year":"2024","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"zoi260671r24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12905-022-01911-x","article-title":"Does access to no-cost contraception change method selection among individuals who report difficulty paying for health-related care?","volume":"22","author":"Gero","year":"2022","journal-title":"BMC Womens Health"},{"issue":"5","key":"zoi260671r25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1089\/jwh.2015.5191","article-title":"Preventing unintended pregnancy: the contraceptive CHOICE Project in review.","volume":"24","author":"Birgisson","year":"2015","journal-title":"J Womens Health (Larchmt)"},{"issue":"3","key":"zoi260671r26","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.105102","article-title":"Contraception in women with medical comorbidities: clinical risk stratification and individualized therapeutic strategies.","volume":"18","author":"Castro Rivero","year":"2026","journal-title":"Cureus"},{"key":"zoi260671r27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bpobgyn.2020.05.003","article-title":"Progesterone and endometrial cancer.","volume":"69","author":"Gompel","year":"2020","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"5","key":"zoi260671r28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/humupd\/dmv023","article-title":"Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods.","volume":"21","author":"Bahamondes","year":"2015","journal-title":"Hum Reprod Update"},{"issue":"2","key":"zoi260671r29","first-page":"1","article-title":"Births: final data for 2022.","volume":"73","author":"Osterman","year":"2024","journal-title":"Natl Vital Stat Rep"},{"issue":"12","key":"zoi260671r30","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1001\/jamaoncol.2025.4480","article-title":"Hormonal contraceptive formulations and breast cancer risk in adolescents and premenopausal women.","volume":"11","author":"Hadizadeh","year":"2025","journal-title":"JAMA Oncol"},{"issue":"12","key":"zoi260671r31","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1111\/1471-0528.12768","article-title":"Bleeding patterns during the menopausal transition in the multi-ethnic Study of Women\u2019s Health Across the Nation (SWAN): a prospective cohort study.","volume":"121","author":"Paramsothy","year":"2014","journal-title":"BJOG"},{"key":"zoi260671r11","unstructured":"National Health and Nutrition Examination Survey. Centers for Disease Control and Prevention. Accessed February 10, 2024. https:\/\/www.cdc.gov\/nchs\/nhanes"},{"key":"zoi260671r13","unstructured":"National Health and Nutrition Examination Survey: 1988-2020 data documentation, codebook, and frequencies: prescription medications\u2014drug information (RXQ_DRUG). Centers for Disease Control and Prevention. Accessed January 10, 2025. https:\/\/wwwn.cdc.gov\/Nchs\/Data\/Nhanes\/Public\/1988\/DataFiles\/RXQ_DRUG.htm"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851738\/bacha_2026_oi_260671_1783701518.77641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:30:24Z","timestamp":1784302224000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.23880","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}